Coherus BioSciences

Today, we’re honoring all those who have served our country. Thank you for your bravery. #VeteransDay 

Don’t miss our presentation today at SITC 2024 on CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses. View our poster https://bit.ly/3YaEEEg #oncology #CCR8

Attending SITC 2024? Stop by our presentation today to learn more about Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment and its potential to promote NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors. View the poster: https://bit.ly/3XUGZSH #oncology

Join us for our Q3 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q3 financial results and recent business highlights. Press release: https://bit.ly/3ChZ465 Listen to the webcast: https://bit.ly/4e9J1UU

Coherus will report Q3 2024 financial results on November 6, 2024. Starting at 5 pm EDT, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q3 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4e9J1UU

Attending Cytokines 2024-KAI 2024? Meet with Theresa LaVallee, our Chief Development Officer, to learn more about our IL-27 antagonist, casdozokitug. Dr. LaVallee will present data for casdozokitug (abstract P2-CI096) during the cancer immunology and immunotherapy poster session on October 21st in Poster Area 3. 

Congratulations to Coherus Board Member Jill O'Donnell-Tormey for being honored at the Cancer Research Institute (CRI) Annual Awards Gala! Dr. O'Donnell-Tormey has been awarded the 2024 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. We’re proud to have her leadership and support as a valued member of our board. #leadership #biotech #oncology 

Congratulations to our Chief Development Officer, Dr. Theresa LaVallee, for being recognized by Endpoints News as one of the top 20 women breaking barriers in drug development and inspiring the next generation of leaders. Join us in celebrating all the honorees at ENDPOINTS’ virtual event on October 8th at 11am ET. #biotech #leadership #oncology Register here: https://bit.ly/3Zmn8hy

Coherus is heading to Houston for the Society for Immunotherapy of Cancer (SITC) 2024! Our team is excited to be presenting data on casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promoting NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors, and CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses. #oncology

#ICYMI: Dr. Shawn Wang presented data at #CICON24 from the dose escalation stage of our Phase 1 study of CHS-114, an anti-CCR8 mAb, showing intratumoral Treg depletion and immune activation in heavily pretreated cancer patients. View the poster: https://bit.ly/4dVbBtx #CCR8